Clinical efficacy and prognostic observation of Yiqi Fumai combined with levosimendan in the treatment of ischemic cardiomyopathy with heart failure
Objective To investigate the clinical efficacy and prognosis of Yiqi Fumai combined with levosimendan in the treatment of ischemic cardiomyopathy with heart failure.Methods A total of 120 patients with ischemic cardiomyopathy and heart failure admitted to Harbin Fourth Hospital from January 2022 to June 2023 were selected as the research subjects.They were randomly divided into a control group(n=60,treated with levosimendan)and an observation group(n=60,treated with levosimendan+Yiqi Fumai)using a random number list method.Echocardiographic indices,six-minute walking experiment(6MWT),N-terminal pro-B-type natriuretic peptide(NT-proBNP)levels,adverse reactions(ADRs)and short-term prognosis were compared between the two groups.Results After 7 days of treatment,the observation group showed more significant improvements in left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),and left ventricular end diastolic diameter(LVEDD)compared to the control group(P＜0.05).After 7 days of treatment,the observation group showed better improvement in NT proBNP and 6MWT walking distance compared to the control group(P＜0.05).There was no statistically significant difference in the incidence of ADRs between the two groups(P＞0.05).During the 6-month follow-up,the readmission rate and mortality rate of the observation group were lower than those of the control group(P＜0.05).Conclusion Yiqi fumai combined with levosimendan can effectively improve the cardiac function of patients with ischemic cardiomyopathy and heart failure,with good safety,and can obviously improve the short-term prognosis of patients.
万方数据
维普
